These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for Teriparatide
Last updated: February 20, 2026
Teriparatide (brand name: Forteo) is a recombinant form of parathyroid hormone used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. Its unique anabolic mechanism makes it a critical therapy for severe cases. The following provides a market overview, competitive landscape, pricing trends, and future projections.
Market Overview
Current Market Size
The global osteoporosis drug market was valued at approximately $11 billion in 2022. Teriparatide accounted for an estimated $1.2 billion of this, reflecting its niche status relative to bisphosphonates. The drug's use is limited to specific high-risk populations, constraining its market share.
Key Markets
United States: Largest market, driven by high osteoporosis prevalence, insurance coverage, and FDA approval since 2002.
Europe: Significant adoption, with national health systems supporting reimbursement.
Asia-Pacific: Rapid growth due to aging populations and increased healthcare access, though market penetration remains nascent.
Market Drivers
Rising awareness of osteoporosis complications.
Aging demographics globally.
Advancements in treatment guidelines endorsing anabolic therapies.
Limited competition; teriparatide remains one of the few approved anabolic agents.
Market Challenges
High cost and administration route (daily injections).
Safety concerns related to osteosarcoma (pediatric safety data) limiting long-term use.
Competition from newer agents, including abaloparatide and romosozumab.
Competitive Landscape
Primary Competitors
Drug
Class
Approval Year
Key Features
Market Share (2022)
Teriparatide
Recombinant PTH
2002 (FDA)
Daily subcutaneous injection; proven efficacy
50%
Abaloparatide
PTH-related peptide analog
2017 (FDA)
Similar to teriparatide; once-daily injection
25%
Romosozumab
Sclerostin inhibitor
2019 (FDA)
Monthly injection; anabolic and antiresorptive effects
20%
Patent and Licensing Status
Patents for Forteo expired in 2018, leading to biosimilar development.
Several biosimilars entered the market in 2020–2022, reducing prices and expanding access.
Price Trends and Projections
Current Pricing
United States: Teriparatide costs approximately $6,500–$8,000 per year for branded Forteo.
Biosimilars: Priced around $4,000–$5,000, representing a 20–40% discount.
Reimbursement: Insurance coverage varies; Medicare covers most patients under specific conditions.
Historical Trends
Prices remained stable from 2005–2015.
A gradual decline began with biosimilar entry in 2020.
Price reductions accelerated in 2021–2022 due to increased biosimilar availability.
Innovations in drug delivery reducing administration costs.
Market Outlook and Strategic Considerations
The anabolic segment remains limited but robust due to unmet needs in severe osteoporosis.
Biosimilar proliferation is expected to cut costs further, expanding access.
Development of oral anabolic agents could disrupt the market.
Strategic focus on high-risk populations ensures sustained demand for teriparatide.
Key Takeaways
The global osteoporosis therapy market is expected to grow at a CAGR of approximately 5% through 2030.
Teriparatide's market share is declining slowly due to biosimilars and new therapies.
Prices for teriparatide are projected to decline 25–50% over the next decade, driven primarily by biosimilar entry.
Reimbursement policies and demonstration of long-term safety will influence market dynamics.
Competition from newer agents, especially romosozumab, may impact market share and price stability.
FAQs
What factors could halt the declining price trend for teriparatide?
Major safety concerns or regulatory hurdles that delay biosimilar entry or restrict use could stabilize prices.
How does biosimilar entry affect market competition?
Biosimilars introduce lower-cost options, driving prices downward and increasing access, but may also impact revenue for original manufacturers.
Are new anabolic therapies likely to replace teriparatide?
Potentially. Agents like abaloparatide and romosozumab offer similar or enhanced efficacy, possibly capturing larger market segments.
What is the outlook for patent extensions for teriparatide?
Patent expirations in 2018 led to biosimilar development; extensions are unlikely unless new formulations or delivery methods emerge.
How do regulatory policies influence drug prices?
Policies prioritizing biosimilar approval, price negotiation, and reimbursement criteria significantly shape price trajectories.
References
[1] MarketWatch. (2023). "Global Osteoporosis Drugs Market Analysis."
[2] IQVIA. (2022). "Pharmaceutical Market Trends."
[3] FDA. (2022). "Approval History of Teriparatide."
[4] EvaluatePharma. (2023). "Pricing and Market Share Data for Osteoporosis Therapies."
[5] European Medicines Agency. (2022). "Biosimilar Approvals and Market Impact."
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
